| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating | 
|---|
 
																	- SEC Filing
 
																	 
																	Canaccord Genuity analyst Kyle Mikson downgrades Quanterix (NASDAQ:QTRX) from Buy to Hold and lowers the price target from $...
 
																	Quanterix (NASDAQ:QTRX) reported quarterly losses of $(0.47) per share which missed the analyst consensus estimate of $(0.45) b...
 
																	Quanterix (NASDAQ:QTRX) raises FY2025 sales outlook from $120.000 million-$130.000 million to $130.000 million-$135.000 million...
 
																	
 
																	
 
																	 
																	Company highlights expanded capabilities following Akoya Biosciences Acquisition and Simoa® technology included in more than 55...